Is it safe to prescribe empagliflozin (Jardiance) to an 82‑year‑old woman with a galectin‑3 level above 30 ng/mL?

Empagliflozin is safe and appropriate for an 82-year-old woman with elevated galectin-3 levels

Empagliflozin can be safely prescribed to this patient, provided her eGFR is ≥20 mL/min/1.73 m² and she does not have contraindications such as dialysis dependence or severe hypersensitivity. The elevated galectin-3 level (>30 ng/mL) actually suggests increased cardiovascular and heart failure risk, making SGLT2 inhibitor therapy particularly beneficial rather than contraindicated 1, 2.

Key Safety Considerations by Patient Factors

Age-Related Safety Profile

Empagliflozin has been extensively studied in elderly populations with favorable outcomes. In the EMPA-REG OUTCOME trial, 32% of patients were ≥65 years and 6% were ≥75 years 2. Safety and efficacy were similar across age groups, with cardiovascular mortality reduction maintained in patients ≥75 years (HR 0.55,95% CI 0.32-0.94) 3. The FDA label specifically confirms that safety and efficacy were similar for patients 65 years and younger versus those older than 65 years 2.

Critical Age-Specific Risks to Monitor

In patients ≥75 years, there are modestly increased risks that require monitoring but do not preclude use 2:

• Volume depletion: increased to 4.4% with empagliflozin 25 mg versus 2.1% with placebo
• Urinary tract infections: increased to 15.1-15.7% versus 10.5% with placebo
• Assess volume status before initiation and correct any volume depletion 2

Renal Function Requirements

The most critical safety parameter is kidney function, not age or galectin-3 level:

• For heart failure indication: Can initiate if eGFR ≥20 mL/min/1.73 m² 1, 2
• For glycemic control: Not recommended to initiate if eGFR <30 mL/min/1.73 m² 1
• For cardiovascular disease with diabetes: Insufficient data below eGFR 20 mL/min/1.73 m² 2
• Once initiated, continue even if eGFR declines below initiation threshold unless dialysis is started 1

Galectin-3 Context

Elevated galectin-3 (>30 ng/mL) is a biomarker of cardiac fibrosis, inflammation, and heart failure risk 4, 5. This elevation indicates the patient is at higher cardiovascular risk, which strengthens rather than weakens the indication for empagliflozin. SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization regardless of baseline risk markers 1, 6. Recent data show empagliflozin reduces kidney injury molecule-1 (KIM-1) by 38%, demonstrating renal tubular protection in heart failure patients with diabetes 7.

Practical Initiation Protocol

Pre-Initiation Assessment

1. Check eGFR: Must be ≥20 mL/min/1.73 m² for heart failure or ≥30 mL/min/1.73 m² for glycemic control 2
2. Assess volume status: Correct volume depletion before starting, especially critical in elderly 8, 1
3. Review diuretics: Consider proactive dose reduction if on high-dose diuretics 1
4. Insulin/sulfonylurea adjustment: May reduce insulin by ~20% or reduce sulfonylurea dose to prevent hypoglycemia 9

Dosing

• Start with 10 mg once daily (the dose studied in cardiovascular outcomes trials) 9, 2
• Take with or without food 2
• No dose adjustment needed for age alone 2
• Can increase to 25 mg for additional glycemic benefit if tolerated, though cardiovascular/renal benefits occur at 10 mg 1

Monitoring Strategy

• Volume status and blood pressure at 1-2 weeks, especially if ≥75 years 1, 2
• Genital hygiene counseling: Women have 10-15% risk of genital mycotic infections versus 1% with placebo 1
• Ketoacidosis education: Rare but serious; maintain at least low-dose insulin if insulin-requiring, hold during acute illness 1
• eGFR monitoring: Every 3-6 months; expect initial reversible decline of 3-5 mL/min/1.73 m² 1

Contraindications and Cautions

Absolute Contraindications

• Dialysis dependence 2
• History of serious hypersensitivity to empagliflozin 2

Relative Cautions (Not Contraindications)

• Hypotension or low systolic BP: Assess volume status carefully 8
• Recurrent UTIs: Monitor closely, particularly in women ≥75 years 2
• Type 1 diabetes: Not indicated due to ketoacidosis risk 2

Sick Day Protocol

Temporarily discontinue empagliflozin during 1:

• Acute illness with reduced oral intake
• Planned surgery (stop 3-4 days before) 1
• Critical illness or prolonged fasting
• Signs of ketoacidosis (nausea, vomiting, abdominal pain, fatigue)

Evidence Quality

The recommendation is based on high-quality evidence from multiple sources:

• 2022 ADA/KDIGO consensus strongly recommends SGLT2 inhibitors for patients with diabetes and eGFR ≥20 mL/min/1.73 m² 1
• 2025 ADA Standards of Care confirm use in older adults with appropriate monitoring 10, 11
• FDA label explicitly addresses geriatric use with favorable safety profile 2
• EMPA-REG OUTCOME subgroup analysis demonstrated consistent benefit in patients ≥75 years 3

The combination of advanced age and elevated galectin-3 represents increased cardiovascular risk, making empagliflozin particularly appropriate rather than contraindicated, provided renal function and volume status are adequate.